secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041299
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q2 2023 net loss $31.8M; cash $365.3M, funding into H2 2025
------------------------------------------------------------------

- Net loss of $31.8M ($0.21/ share) vs $35.6M ($0.30) in Q2 2022; R&D spend $26.2M.
- Cash, equivalents, and marketable securities $365.3M as of Jun 30, 2023, down from $435.6M at Dec 31, 2022.
- ERAS-007 Phase 1b in BRAFm CRC showed 50% (3/6) response rate; expansion data expected H2 2023–H1 2024.
- First patient dosing in SEACRAFT-1 (naporafenib + trametinib) for RAS Q61X tumors expected H2 2023.
- FDA granted Fast Track and Orphan Drug Designations for ERAS-801 in recurrent glioblastoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/0000950170-23-041299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/eras-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer